A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

PHASE3CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

June 24, 2022

Study Completion Date

December 16, 2022

Conditions
RabiesCommunicable DiseaseVirus DiseasesRhabdoviridae InfectionsMononegavirales InfectionsRNA Virus Infections
Interventions
BIOLOGICAL

SYN023

The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.

BIOLOGICAL

Human Rabies Immune Globulin (HRIG)

The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies

BIOLOGICAL

Rabies Vaccine

Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29

Trial Locations (1)

650022

Yunnan Province Center for Disease Control and Prevention (CDC), Kunming

All Listed Sponsors
collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

lead

Synermore Biologics (Suzhou) Co., Ltd.

INDUSTRY

NCT04644484 - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety | Biotech Hunter | Biotech Hunter